These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29392687)

  • 1. Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma.
    Wrzeszczynski KO; Felice V; Shah M; Rahman S; Emde AK; Jobanputra V; O Frank M; Darnell RB
    Methods Mol Biol; 2018; 1741():1-29. PubMed ID: 29392687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
    Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability.
    Lindstrand A; Eisfeldt J; Pettersson M; Carvalho CMB; Kvarnung M; Grigelioniene G; Anderlid BM; Bjerin O; Gustavsson P; Hammarsjö A; Georgii-Hemming P; Iwarsson E; Johansson-Soller M; Lagerstedt-Robinson K; Lieden A; Magnusson M; Martin M; Malmgren H; Nordenskjöld M; Norling A; Sahlin E; Stranneheim H; Tham E; Wincent J; Ygberg S; Wedell A; Wirta V; Nordgren A; Lundin J; Nilsson D
    Genome Med; 2019 Nov; 11(1):68. PubMed ID: 31694722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
    McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
    Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLL.
    Klintman J; Barmpouti K; Knight SJL; Robbe P; Dreau H; Clifford R; Ridout K; Burns A; Timbs A; Bruce D; Antoniou P; Sosinsky A; Becq J; Bentley D; Hillmen P; Taylor JC; Caulfield M; Schuh AH
    Br J Haematol; 2018 Aug; 182(3):412-417. PubMed ID: 29808933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants.
    Belkadi A; Bolze A; Itan Y; Cobat A; Vincent QB; Antipenko A; Shang L; Boisson B; Casanova JL; Abel L
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5473-8. PubMed ID: 25827230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer.
    Wrzeszczynski KO; Felice V; Abhyankar A; Kozon L; Geiger H; Manaa D; London F; Robinson D; Fang X; Lin D; Lamendola-Essel MF; Khaira D; Dikoglu E; Emde AK; Robine N; Shah M; Arora K; Basturk O; Bhanot U; Kentsis A; Mansukhani MM; Bhagat G; Jobanputra V
    J Mol Diagn; 2018 Nov; 20(6):822-835. PubMed ID: 30138725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of tools for variant analysis of next-generation genome sequencing data.
    Pabinger S; Dander A; Fischer M; Snajder R; Sperk M; Efremova M; Krabichler B; Speicher MR; Zschocke J; Trajanoski Z
    Brief Bioinform; 2014 Mar; 15(2):256-78. PubMed ID: 23341494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the performance of copy number variant prediction tools for the detection of deletions from whole genome sequencing data.
    Whitford W; Lehnert K; Snell RG; Jacobsen JC
    J Biomed Inform; 2019 Jun; 94():103174. PubMed ID: 30965134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.
    Francis JM; Zhang CZ; Maire CL; Jung J; Manzo VE; Adalsteinsson VA; Homer H; Haidar S; Blumenstiel B; Pedamallu CS; Ligon AH; Love JC; Meyerson M; Ligon KL
    Cancer Discov; 2014 Aug; 4(8):956-71. PubMed ID: 24893890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
    Kunkle B; Yoo C; Roy D
    Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole genome sequencing analysis for cancer genomics and precision medicine.
    Nakagawa H; Fujita M
    Cancer Sci; 2018 Mar; 109(3):513-522. PubMed ID: 29345757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
    Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
    Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
    Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
    Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NGS for Sequence Variants.
    Teng S
    Adv Exp Med Biol; 2016; 939():1-20. PubMed ID: 27807741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
    Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
    J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved molecular karyotyping in glioblastoma.
    Burbulis IE; Wierman MB; Wolpert M; Haakenson M; Lopes MB; Schiff D; Hicks J; Loe J; Ratan A; McConnell MJ
    Mutat Res; 2018 Sep; 811():16-26. PubMed ID: 30055482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
    Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
    J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Whole Genome Sequencing Data.
    Hübschmann D; Schlesner M
    Methods Mol Biol; 2019; 1956():321-336. PubMed ID: 30779042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.